TriSalus Life Sciences, Inc.
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
TLSI$2.85-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Three months ended March 31, 2025 and 2024
(unaudited, in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss available to common stockholders | $(10,375) | $(13,206) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 172 | 175 |
| Reduction in the carrying amount of right-of-use assets | 173 | 76 |
| Change in fair value of warrants and SEPA liabilities | 758 | (2,521) |
| Change in fair value of OrbiMed Warrants and revenue base redemption liabilities | 77 | — |
| Change in fair value of contingent earnout liability | 820 | 3,988 |
| Non-cash interest expense | 266 | — |
| Stock-based compensation expense | 1,620 | 1,086 |
| Allowance for credit losses | 39 | — |
| Loss on disposal of property and equipment | 117 | 18 |
| Amortization of debt issuance costs | 235 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (366) | (723) |
| Inventory, net | (114) | (368) |
| Prepaid expenses | 511 | 955 |
| Deposits | — | 43 |
| Operating lease liabilities | (56) | (85) |
| Trade payables and accrued liabilities | 1,624 | (305) |
| Net cash used in operating activities | (4,499) | (10,867) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (754) | (66) |
| Proceeds from the disposal of property and equipment | 40 | — |
| Net cash used in investing activities | (714) | (66) |
| Cash flows from financing activities: | ||
| Proceeds from the issuance of common stock | — | 3,141 |
| Debt issuance costs | (520) | — |
| Proceeds from the issuance of debt | 10,000 | — |
| Payments on finance lease liabilities | (71) | (22) |
| Proceeds from the exercise of stock options for common stock | 279 | 7 |
| Net cash provided by financing activities | 9,688 | 3,126 |
| Increase (decrease) in cash, cash equivalents and restricted cash | 4,475 | (7,807) |
| Cash, cash equivalents and restricted cash, beginning of period | 8,875 | 12,127 |
| Cash, cash equivalents and restricted cash, end of period | $13,350 | $4,320 |
| Supplemental disclosures of cash flow information: | ||
| Interest paid | $709 | $3 |
| Income taxes | $1 | $— |
| Supplemental disclosures of non-cash items: | ||
| Right-of-use assets obtained in exchange for new operating lease liabilities | $— | $90 |
| Fixed asset purchase through exchange of finance lease right-of-use asset | $85 | $— |
| Derecognition of finance lease right-of-use asset | $(85) | $— |
| Fixed asset purchases included in trade payables and accrued expenses | $87 | $— |
| Fair value of warrants issued related to OrbiMed debt | $366 | $— |
| Non-cash interest expense | $266 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.